<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00698893</url>
  </required_header>
  <id_info>
    <org_study_id>208141/001</org_study_id>
    <nct_id>NCT00698893</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults</brief_title>
  <official_title>An Open Study in Healthy Herpes Simplex Virus (HSV)-Positive Adults to Evaluate the Safety of GSK Biologicals' Candidate gD Vaccine, With or Without 3D MPL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and reactogenicity of candidate gD
      vaccine, with or without MPL, in HSV-seropositive subjects. The immune response elicited in
      these subjects will also be evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former
      name SmithKline Beecham
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 1992</start_date>
  <completion_date type="Actual">July 1, 1992</completion_date>
  <primary_completion_date type="Actual">July 1, 1992</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the vaccine safety by repeated physical examination and by recording all local and general signs/symptoms</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of haematology/biochemical parameters on blood samples</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine reactogenicity by soliciting of local and general signs/symptoms</measure>
    <time_frame>On the day of vaccination and the subsequent 7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vaccine immunogenicity by 6 measurements of anti-HSV antibodies</measure>
    <time_frame>From day 0 to day 45 following vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Herpes Simplex</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herpes simplex candidate (gD) vaccine GSK208141</intervention_name>
    <description>Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 40 years of age

          -  Seropositive for antibodies against HSV

          -  Female volunteers must have been using contraceptives for at least 2 months before the
             entry and should avoid becoming pregnant for the duration of this study.

          -  Good physical condition as established by physical examination and history taking at
             the time of entry

        Exclusion Criteria:

          -  Any abnormal laboratory value among the tests performed at screening.

          -  History of persistent hepatic, renal, cardiac or respiratory diseases

          -  Clinical signs of acute illness at the time of entry into the study.

          -  Previous history of asthma or hypersensitivity to drugs.

          -  Seropositive for antibodies against the human immunodeficiency virus

          -  Pregnancy and lactation.

          -  Treatment with corticosteroids or immunomodulating drugs.

          -  Simultaneous participation in another clinical trial.

          -  Administration of any other vaccine or immunoglobulins during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/208141/001?search=study&amp;#rs</url>
    <description>Results for study 208141/001 can be found on the GSK Clinical Study Register</description>
  </link>
  <reference>
    <citation>Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008 Dec 2;26(51):6630-8. doi: 10.1016/j.vaccine.2008.09.049.</citation>
    <PMID>18845199</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Herpes simplex</keyword>
  <keyword>Herpes simplex candidate (gD) vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

